BNET Industries
Market Cap:$148.4B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Pfizer Raises Quarterly Dividend 13%, See More Annual Hikes
-
Pfizer lifts dividend, yield closer to rivals
-
BRIEF: SEC probing insider-trading allegations
-
Pfizer joins partnership with Calif. firm: Collaboration planned with Crown Bioscience for cancer research
-
Research and Markets: The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to...
-
Science and Technology: Pfizer to buy Croatian drug patent
-
Bristol-Myers Squibb Raises Exchange Offer Price For Mead Johnson Shares - Update
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Survey of Alberta nonprofits shows revenues continue to decline
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Market Report -- In Play PFE
-
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher's Disease
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Conservationists salute two corporations
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
2009: The Year That Was For Pfizer
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
News & Analysis
Filter by
john maas and pfizer inc. and pharmaceutical company - All News and Analysis
Pharma Roundup: Lilly's Zyprexa Settlement; Cuts at Pfizer, Roche; and More
BNET
- 2009-01-15
Lilly's Zyprexa settlment is biggest ever; Pfizer may cut 2,400; Roche cuts 780; Novartis' Ebeling on the future of pharma. by John Maas
Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More
BNET
- 2009-01-05
Pfizer wants acquisitions, big and small. Prasugrel has a date with the FDA. New Year's blog feature bonanza. Farewell, Pharmalot. by John Maas
Pharma Roundup: AstraZeneca and Teva Mend Fences, Barbara Ryan's M&A Speculation, and More
BNET
- 2008-11-25
AstraZeneca and Teva settle a potentially-acrimonious patent battle. Barbara Ryan speculates on pharma M&A. EU criticizes "strategic patenting." Indonesia wants drug production facilities from Big Pharma. by John Maas
Pharma Roundup: Amylin Cuts Jobs, Sanofi Faces Hard Times, and More
BNET
- 2008-11-11
Amylin cuts 340 jobs, UBS predicts hard times for Sanofi, Pfizer sells a factory and GSK will close one. by John Maas
Pharma Roundup: AstraZeneca's Crestor Success, Pfizer's Chantix Problems, and More
BNET
- 2008-11-10
Highly encouraging results on AZ's Crestor, UK drug regulators echo Chantix suicide concerns, OTC drug marketers struggle, Lilly CEO highlights three "gorillas" dogging pharma. by John Maas
Pharma Roundup: Glaxo Reorganizing in U.S., Pfizer Urged to Keep Jobs in Connecticut, and More
BNET
- 2008-11-04
Glaxo reorganizes U.S. operations; Connecticut congressmen ask Pfizer to keep U.S. jobs; AstraZeneca executive Patterson to retire; DTC advertising not earning its keep? by John Maas
Pharma Roundup: Pfizer Buys Biotene, JAMA Opposes Wyeth, and More
BNET
- 2008-10-21
Pfizer buys Biotene; JAMA editorial against drug makers in Wyeth preemption case; pharma companies behind the times on Web 2.0; Roche still vowing to buy Genentech by John Maas
Pharma Roundup: Wyeth Slimming Distribution Network, Pfizer Suppressed Study, and More
BNET
- 2008-10-08
Wyeth eliminates East Coast distributor; Pfizer suppressed Neurontin study; entrepreneur urges rescue of U.K. biotech industry; pharma companies now contributing to McCain. by John Maas
Pharma Roundup: Pfizer Re-Slices Organizational Pie, Lilly Dishes Out Zyprexa Settlement, and More
BNET
- 2008-10-07
Pfizer reorganizes; Lilly to pay $62 million fine over Zyprexa; biotech losing talent to clean tech; Consumer Reports blacklists 20 drugs for seniors by John Maas
Pharma Roundup: Merck Gets Transparent, Pfizer Mulls Layoffs, and More
BNET
- 2008-09-25
Merck latest to announce transparency policies -- As the Physician Payments Sunshine Act approaches Congressional approval, Merck has announced a plan to publicize the grants they offer medical organizations and speakers. Earlier this week, Lilly made a similar promise, and several other pharma companies have recently retooled their disclosure policies....
- 1
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
Presented by American Express